Tags

Type your tag names separated by a space and hit enter

Clinical and MRI phenotype of children with MOG antibodies.
Mult Scler. 2016 Feb; 22(2):174-84.MS

Abstract

OBJECTIVE

To investigate the clinical and magnetic resonance imaging (MRI) features of anti-myelin oligodendrocyte glycoprotein (MOG) antibody-seropositive pediatric demyelinating syndromes.

METHODS

Serum samples collected from 74 children with suspected demyelinating disorders whom were being followed at Massachusetts General Hospital were incubated with control green fluorescent protein (GFP)- and MOG-GFP-transfected Jurkat cell clones. The binding ratios were calculated using flow cytometry. Using statistical analyses, we compared the demographic, clinical and radiological features in our seropositive and seronegative patients.

RESULTS

We found that 13 out of 74 (17.5%) patients were seropositive for MOG. The MOG-seropositive patients were younger than the seronegative patients (p = 0.049). No single disease category predominated among the seropositive patients, nor was one group more likely to have a polyphasic course. There were two out of four neuromyelitis optica (NMO) patients who had MOG antibodies; both were seronegative for aquaporin -4 (AQP4) antibodies. One had monophasic disease and the other had frequent relapses. There was a bimodal distribution of the MOG-seropositive patients by age at onset, with a distinct younger group (4-8 years) having a high prevalence of encephalopathy and an older group (13-18 years), whom presented almost exclusively with optic neuritis. MRI analysis demonstrated the absence of corpus callosum lesions in the seropositive patients (p = 0.012). The annualized relapse rate (ARR) and the Expanded Disability Status Scale (EDSS) results at 2 years did not differ between the seropositive and seronegative patients.

CONCLUSION

MOG antibodies are found across a variety of pediatric demyelinating syndromes having some distinct clinical and MRI features.

Authors+Show Affiliations

Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA.Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA.Partners MS Center, Brigham and Women's Hospital, Boston, MA, USA.Partners MS Center, Brigham and Women's Hospital, Boston, MA, USA/Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA.Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, MA, USA.Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, MA, USA.Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA/Partners MS Center, Brigham and Women's Hospital, Boston, MA, USA/Partners Pediatric MS Center, Massachusetts General Hospital, Boston, MA, USA tchitnis@partners.org.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26041801

Citation

Fernandez-Carbonell, Cristina, et al. "Clinical and MRI Phenotype of Children With MOG Antibodies." Multiple Sclerosis (Houndmills, Basingstoke, England), vol. 22, no. 2, 2016, pp. 174-84.
Fernandez-Carbonell C, Vargas-Lowy D, Musallam A, et al. Clinical and MRI phenotype of children with MOG antibodies. Mult Scler. 2016;22(2):174-84.
Fernandez-Carbonell, C., Vargas-Lowy, D., Musallam, A., Healy, B., McLaughlin, K., Wucherpfennig, K. W., & Chitnis, T. (2016). Clinical and MRI phenotype of children with MOG antibodies. Multiple Sclerosis (Houndmills, Basingstoke, England), 22(2), 174-84. https://doi.org/10.1177/1352458515587751
Fernandez-Carbonell C, et al. Clinical and MRI Phenotype of Children With MOG Antibodies. Mult Scler. 2016;22(2):174-84. PubMed PMID: 26041801.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical and MRI phenotype of children with MOG antibodies. AU - Fernandez-Carbonell,Cristina, AU - Vargas-Lowy,David, AU - Musallam,Alexander, AU - Healy,Brian, AU - McLaughlin,Katherine, AU - Wucherpfennig,Kai W, AU - Chitnis,Tanuja, Y1 - 2015/06/03/ PY - 2014/12/05/received PY - 2015/04/18/accepted PY - 2015/6/5/entrez PY - 2015/6/5/pubmed PY - 2017/1/11/medline KW - Acute disseminated encephalomyelitis KW - demyelinating syndromes KW - encephalopathy KW - glycoprotein KW - magnetic resonance imaging KW - multiple sclerosis KW - myelin KW - myelin oligodendrocyte glycoprotein KW - neuromyelitis optica KW - optic neuritis KW - pediatric multiple sclerosis KW - serology SP - 174 EP - 84 JF - Multiple sclerosis (Houndmills, Basingstoke, England) JO - Mult Scler VL - 22 IS - 2 N2 - OBJECTIVE: To investigate the clinical and magnetic resonance imaging (MRI) features of anti-myelin oligodendrocyte glycoprotein (MOG) antibody-seropositive pediatric demyelinating syndromes. METHODS: Serum samples collected from 74 children with suspected demyelinating disorders whom were being followed at Massachusetts General Hospital were incubated with control green fluorescent protein (GFP)- and MOG-GFP-transfected Jurkat cell clones. The binding ratios were calculated using flow cytometry. Using statistical analyses, we compared the demographic, clinical and radiological features in our seropositive and seronegative patients. RESULTS: We found that 13 out of 74 (17.5%) patients were seropositive for MOG. The MOG-seropositive patients were younger than the seronegative patients (p = 0.049). No single disease category predominated among the seropositive patients, nor was one group more likely to have a polyphasic course. There were two out of four neuromyelitis optica (NMO) patients who had MOG antibodies; both were seronegative for aquaporin -4 (AQP4) antibodies. One had monophasic disease and the other had frequent relapses. There was a bimodal distribution of the MOG-seropositive patients by age at onset, with a distinct younger group (4-8 years) having a high prevalence of encephalopathy and an older group (13-18 years), whom presented almost exclusively with optic neuritis. MRI analysis demonstrated the absence of corpus callosum lesions in the seropositive patients (p = 0.012). The annualized relapse rate (ARR) and the Expanded Disability Status Scale (EDSS) results at 2 years did not differ between the seropositive and seronegative patients. CONCLUSION: MOG antibodies are found across a variety of pediatric demyelinating syndromes having some distinct clinical and MRI features. SN - 1477-0970 UR - https://www.unboundmedicine.com/medline/citation/26041801/Clinical_and_MRI_phenotype_of_children_with_MOG_antibodies_ L2 - https://journals.sagepub.com/doi/10.1177/1352458515587751?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -